{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=38", "query": { "intervention": "Gemzar", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 1628, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T00:04:09.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06632951", "title": "Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-01-20", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 11, "location_summary": "Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06632951" }, { "nct_id": "NCT06865339", "title": "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Locally Advanced" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Platinum Doublet Chemotherapy (PDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-08-07", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865339" }, { "nct_id": "NCT02611037", "title": "Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma", "Mesothelioma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lung Cancer Symptom Scale for Mesothelioma Questionnaire", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2016-03-04", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611037" }, { "nct_id": "NCT01004731", "title": "Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cetuximab in combination with Carboplatin/Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2001-06", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004731" }, { "nct_id": "NCT00998322", "title": "A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "REOLYSIN", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2009-10", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-04-10", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 2, "location_summary": "New York, New York • San Antonio, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00998322" }, { "nct_id": "NCT06233877", "title": "Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "G-GLIP plus Mitomycin C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hirschfeld Oncology", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-03-15", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 1, "location_summary": "Brooklyn, New York", "locations": [ { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06233877" }, { "nct_id": "NCT01788566", "title": "A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Necitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2013-03", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-06-27", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Deerfield Beach, Florida • Farmington Hills, Michigan", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Farmington Hills", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01788566" }, { "nct_id": "NCT00053222", "title": "Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2003-02", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 11, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "LaGrange", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053222" }, { "nct_id": "NCT00305786", "title": "Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 30, "start_date": "2005-08", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 2, "location_summary": "Miami, Florida • Tampa, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00305786" }, { "nct_id": "NCT01022996", "title": "Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Everolimus (RAD001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2009-12", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-11-15T00:04:09.356Z", "location_count": 16, "location_summary": "Los Angeles, California • Greenwood Village, Colorado • Orlando, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01022996" } ] }